← ANALYST RATINGS · TIPRANKS
Editas Medicine (EDIT): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $6.00, the highest $8.00, the lowest $5.00. The average is +155.3% from the last price of $2.35.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $2.50+25.0% | Hold | +6.4% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $2.50+25.0% | Hold | +6.4% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Sell | −14.9% | Downgrade | 14.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $6.00 | Buy | +155.3% | Upgrade | 08.10.26on TipRanks 11:15 | +3.7%next day +1.5% · 5 days −13.8% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $5.00 | Buy | +112.8% | Upgrade | 23.09.26on TipRanks 06:15 | −7.2%next day +2.3% · 5 days −3.8% | ↗ |
| Rick Bienkowski★★★★★★★★★★#12090 · hits 19% · avg −23.3% | Ladenburg Thalmann & Co. | $6.00 | Buy | +155.3% | Initiated | 18.08.26on TipRanks 06:50 | +2.1%next day +12.6% · 5 days +14.1% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | — | Sell | — | Reiterated | 07.08.26on TipRanks 15:35 | −1.3%next day −2.4% · 5 days −2.5% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $3.00 → $5.00+66.7% | Buy | +112.8% | Reiterated | 06.08.26on TipRanks 06:35 | +5.6%next day −1.3% · 5 days −4.3% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $4.00 | Hold | +70.2% | Reiterated | 05.08.26on TipRanks Aug 6 07:01 | −0.5%next day +5.6% · 5 days +2.9% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 05.08.26on TipRanks Aug 6 06:05 | −0.5%next day +5.6% · 5 days +2.9% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $8.00 | Buy | +240.4% | Reiterated | 05.08.26on TipRanks 21:06 | +5.6%next day −1.3% · 5 days −4.3% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $15.00 | Buy | +538.3% | Reiterated | 27.05.26on TipRanks 11:05 | +15.9%next day −4.5% · 5 days −22.6% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $4.00 | Buy | +70.2% | Reiterated | 05.05.26on TipRanks 16:55 | +3.1%next day −4.3% · 5 days −9.8% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Hold | — | Reiterated | 17.03.26on TipRanks 07:25 | −3.4%next day −3.1% · 5 days −6.2% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Sell | — | Reiterated | 13.03.26on TipRanks Mar 16 03:35 | −3.4%next day +3.1% · 5 days −2.3% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $4.60 | Buy | +95.7% | Reiterated | 10.03.26on TipRanks 06:35 | +14.0%next day +0.9% · 5 days −5.9% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $3.00 | Hold | +27.7% | Reiterated | 11.11.25on TipRanks 04:00 | +5.3%next day +1.4% · 5 days +1.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Editas Medicine
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $5.60 at a price of $2.57 (+117.9%); now: $5.67 at $2.35 (+141.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 2 | 3 | 4 |
| Buy | 3 | 2 | 2 | 1 | 1 | 1 |
| Hold | 2 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.19 (from $-0.25 to $-0.13). Last quarter: $-0.15.
Sales
Next quarter’s sales estimate — $5M (from $0M to $12M). Last quarter: $12M.
Best top-analyst consensus in the sector · Healthcare
About Editas Medicine
- CEO: Gilmore O'Neill
- Employees: 87
- 11 Hurley Street, Cambridge, MA, 02141, US
- www.editasmedicine.com
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 56 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗